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Y. U¨nlu¨,1* S. Keles¸,2 N. Becit,1 C.U. Koc¸og˘ulları,1 H. Koc¸ak1 and E. Bakan2Departments of 1Cardiovascular Surgery, and 2Biochemistry, Atatu¨rk University, Erzurum, TurkeyObjective. Several studies have shown a relation between hyperhomocysteinaemia and vascular disease. To assess the risk of
deep-vein thrombosis (DVT) associated with hyperhomocysteinaemia, we studied plasma homocysteine levels in patients
with deep-vein thrombosis and in normal control subjects.
Materials and methods. We measured plasma homocysteine levels in 48 patients with deep-vein thrombosis and in 33
healthy controls matched to the patients according to age and sex. Plasma homocysteine levels were measured with high
performance liquid chromatography and fluorescence detection. Hyperhomocysteinaemia was defined as a plasma
homocysteine level about 15 mmol/L in both groups. The diagnosis of all patients with deep-vein thrombosis (nZ48) was
verified by Doppler ultrasonography.
Results. Plasma homocysteine levels were found to be increased in the deep-vein thrombosis group compared the control
group (p!0.001, t-test). The mean plasma homocysteine level in the patients was 17.1 SD 5.13 mmol/L (range 6.4–31.3),
and that in the controls was 9.0 SD 1.27 mmol/L (range 6.0–11.5).
The association between elevated homocysteine levels and venous thrombosis was stronger among men than among women.
Conclusions. The increased plasma homocysteine levels we have observed may have a causative role in the development of
deep-vein thrombosis.Keywords: Deep-vein thrombosis; Hyperhomocysteinaemia; Risk factor.Introduction
Hyperhomocysteinaemia (tHcy) is epidemiologically
associated with an increased risk of myocardial infarc-
tion, stroke and peripheral arterial thrombosis as well as
venous thromboembolism.1–5 Hyperhomocysteinaemia
is a disorder of methionine metabolism. Folic acid is the
major dietary determinant of the plasma homocysteine
(Hcy) concentration, as shown in a Dutch population
study.6 Folate deficiency may be caused by suboptimal
folate intake, by increased physiologic demands and
through altered metabolism of iatrogenic origin. In such
deficiency states, folic acid supplementation will quickly
and efficiently normalise plasma Hcy.5
Normal human plasma contains total concen-
trations of Hcy and its derivative disulfides close to
10 mmol/L, although there is some variation due to
genetic factors, age, sex, menopausal status, and otherChemistry article was present at the 54th Annual
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cysteinaemia is the presence of an abnormally elevated
concentration of plasma or serum the totality of Hcy.
Some authors have defined the quantitative degree of
tHcy by use of terms such as ‘moderate, intermediate,
and severe’ or ‘mild, intermediate, and severe’.8,9
Several studies have shown a relation between mild
tHcy and vascular disease.10–12 Homocystinuria was
diagnosed by measuring Hcy in urine by using
qualitative methods or amino acid analysis that
detected Hcy.8 In classic homocystinuria, half the
vascular complications are of venous origin,13 but
until recently it has been unclear whether mild tHcy is
also a risk factor for venous thrombosis.11,14 In a case-
control study, Falcon et al. found that tHcy was a risk
factor for thrombosis in people younger than 40 years
of age.15,16 Since, tHcy also appears to be common, we
examined the risk of thrombosis in persons with deep-
vein thrombosis (DVT).Materials and Methods
Patients were selected from the files of our clinic. OfEur J Vasc Endovasc Surg 30, 315–318 (2005)
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five of 106 patients were excluded because of positive
tests for thrombophilia.
We recruited the control group through a general
practice in our hospital. We invited 122 people aged
34–71 from this practice to take part in a health survey
of risk factors for cardiovascular disease. Forty-seven
people agreed to participate and the first 33 healthy
persons formed the control group. All patients were
tested for thrombophilia. We tested for antithrombin
III, protein C, protein S, activated protein C resistance,
lupus anticoagulant, prothrombin time, activated
partial thromboplastin time, bleeding time, and plate-
let count in this group. We excluded volunteers from
the control group when any test was positive.
Forty-eight patients (14 women, 34 men) presenting
with DVT between 1999 and 2001 were included in the
study. The diagnosis was confirmed by duplex
ultrasonography in all patients. Of these patients 33
presented with an acute DVT while the remainder (nZ
15) had recurrent DVT following an earlier episode.
All patients (nZ15) with a history of recurrent venous
thrombosis were managed by oral anticoagulant
therapy and are registered at our clinic. The patients
with recurrent DVT had had two or more episodes of
venous thrombosis. From this group we excluded
those with thrombophilia (protein C, protein S, and
antithrombin III deficiency), cardiorespiratory and
rheumatic diseases requiring extensive medical
therapy, known malignant tumours, pregnancy, and
other contraindications for oral anticoagulation
therapy (severe arterial hypertension, severe hepatic
failure, recent peptic ulcer disease, and so forth). We
obtained a short medical history from all patients by
interview and all controls by questionnaire.
We obtained blood samples from the antecubital
vein at 08.00 h in 5 mL vacutainer tubes and 4–5 mL
EDTA vacuum glass tubes for determination of the
Hcy. The EDTA-samples for Hcy measurement were
immediately placed on ice and centrifuged at 3500g for
5 min within 15 min of venesection. The plasma was
separated and stored at K20 8C until analysis
(approximately 3 months).
The total Hcy concentration was measured by an
isocratic system with high performance liquid chro-
matography (HPLC) pump (flow rate 1.7 mL/min),
injector (injection volume 20 mL, analytical run time 4–
5 min) and fluorescence detector (Ex: 385 nm, Em:
515 nm) (HP 1100). Hyperhomocysteinaemia was
defined as a plasma Hcy level above 15 mmol/L in
both groups.
In order to evaluate the possibility of a dose-
response relation, we stratified the patients and
controls according to their Hcy concentrations andEur J Vasc Endovasc Surg Vol 30, September 2005calculated odds ratios for thrombosis in the patients at
the higher levels as compared with those at the lowest
level. In addition, we investigated the association
between tHcy and venous thrombosis in men and
women. The local ethics committee approved the
study protocol, and all participants gave their
informed consent. This study was completed as
retrospective case control study with a limited number
of individuals.Statistical analysis
Data are expressed as mean values with standard
deviations. Receiver operating characteristic (ROC)
analysis was used calculate the sensitivity and
specificity of parameters.
An independent sample t-test was used and two-
tailed p value less than 0.05 was considered statisti-
cally significant.
We calculated matched odds ratio to estimate the
relative risk of thrombosis for homocysteine values
above a given point, with the matching factor taken
into account. The 95% confidence intervals were
calculated from a conditional logistic-regression algor-
ithm by the maximum-likelihood method. We also
calculated the cut-off point for Hcy, which was
R11.0 mmol/L.Results
The mean age of the patients with DVT (nZ48; 14
women, 34 men) was 52 years (21–75 years). Thirty-
three patients (9 women, 24 men) recruited contem-
poraneously formed the healthy control group. The
mean age of the patients was 55 years (34–71 years).
The mean plasma Hcy level in the patients was 17.1
SD 5.13 mmol/L (range 6.4–31.3), and that in the
controls was 9.0 SD 1.27 mmol/L (range 6.0–11.5)
(Table 1). The ratio Hcy levels in male to female
subjects among both the patients and the controls was
1.2:1. The Hcy concentrations of individual case
patients and controls are shown as a scattergram in
Fig. 1. The Hcy concentrations between the patients
with DVT and the control group were significantly
different (p!0.001). The mean Hcy levels for men and
women in the patient group were 18.12 SD 5.40 mmol/
L and 14.54 SD 3.35 mmol/L, respectively. The higher
plasma level of tHcy in men than in women was
present at all ages (p!0.01 for the comparison between
the sexes).
The 73rd percentile of the Hcy levels in the control
group was 6–9.9 mmol/L. The cut-off point was
Table 1. Base-line characteristics of the plasma homocysteine values in patients with deep-vein thrombosis and in controls
N Range Minimum Maximum Mean Standard deviation
Control 33 5.5 6.0 11.5 9.0 1.27
Patients 48 24.9 6.4 31.3 17.1 5.13
Patients and control subjects with other thrombophilias have been excluded from this study.
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distribution between the patients with DVT and the
control subjects. These cut-off points are comparable to
the reference values obtained from the patients with
17.1 mmol/L and the controls with 9.0 mmol/L for Hcy
concentration. The 45 patients (93.7%) with DVT had
levels exceeding the cut-off point of 11.0 mmol/L,
versus two patients (6.1%) in the control group. The
results of calculation using other cut-off values is
shown in Table 2. When the cut-off was set at the 90th
percentile, the matched odds ratio for the risk of
venous thrombosis was 2.32 (Table 3).Discussion
Our study shows that tHcy is a risk factor for DVT in
the general population. Our results also suggest that
the association between mild tHcy and DVT is similar
in degree to that reported for tHcy in published
literature.16 We found an increased Hcy concentrationFig. 1. Plasma homocysteine levels in 33 controls and in 48
patients with deep-vein thrombosis.in patients compared to controls. When we analysed
men and women separately, we found a difference in
the risk of thrombosis associated with tHcy, and
women had lower levels of plasma Hcy than men as
discussed by Lussier-Cacan.17
Hyperhomocysteinaemia is a common risk factor
for recurrent venous thrombosis.18 Patients with
homocysteinemia have more frequent thrombotic
complications such as DVT.13
Many hypotheses have been proposed to explain
how tHcy may lead to venous thrombosis. One
hypothesis is that Hcy has a toxic effect on the vascular
endothelium and on the clotting cascade.10,11,16
The normal fasting range of plasma homocysteine-
mia is 5–15 mmol/L.19 Hyperhomocysteinaemia is
considered to be present when plasma Hcy levels
exceed 15 mmol/L.9 Mild increases in plasma Hcy
levels (O16 mmol/L) have been associated with the
presence of vascular disease. A plasma Hcy concen-
tration of more than 22 mmol/L increased the matched
odds ratio for DVT to 4.0.12
We also found an increasing odds ratio for the risk
of DVT with an increasing Hcy concentration. This
finding implies that there is no definite sharp cut-off
point. For Hcy this would be at a level of 11.0 mmol/L
for the fasting value. Determination of odds ratio is
important because of the high prevalence of tHcy in
the general population.
The effect of tHcy was independent of other well-
established risk factors for thrombosis, including
protein C, protein S, and antithrombin III deficiencies
and activated protein C resistance20 since, we soughtTable 2. Results of ROC curve analysis
Control Case patients
Cut-off: 73rd percentile (9.9 mmol/L)
Above cut-off 9 47
Below cut-off 24 1
Cut-off: 85th percentile (10.3 mmol/L)
Above cut-off 5 47
Below cut-off 28 1
Cut-off: 90th percentile (11.0 mmol/L)
Above cut-off 2 45
Below cut-off 31 3
Cut-off: 97.5th percentile (11.5 mmol/L)
Above cut-off 1 42
Below cut-off 32 6
Different cut-off points for homocysteine levels and the effect on the
proportions of controls and patients falling below the resulting level.
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Table 3. Odds ratios for thrombosis associated with hyperhomo-
cysteinaemia
Odds ratio
80th percentile (12.8 mmol/L) 1.98
90th percentile (15.1 mmol/L) 2.32
95th percentile (18.2 mmol/L) 2.57
Y. U¨nlu¨ et al.318and excluded patients with these thrombophilias from
our study.
Ebbesen et al. revealed that the whole blood
coagulation profile was influenced by high plasma
Hcy by (1) prolonging the initiation phase, (2)
increasing the velocity of the coagulation propagation
and (3) increasing the maximum clot firmness. These
changes in whole blood coagulation profile may
contribute to the increased risk of thrombosis in
hyperhomocysteinemic individuals.5 Elevated Hcy
levels may result from low levels of folic acid, vitamin
B6, or vitamin B12. It remains unclear whether tHcy of
different causes entails the same risk of thrombosis.
Nevertheless, it is well known that vitamin sup-
plementation lowers Hcy concentrations and reverses
endothelial dysfunction in almost all subjects with
tHcy, regardless of the underlying cause.16,21
We conclude that mild tHcy is a risk factor for DVT
in the general population.References
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